iSpecimen (ISPC)


Market Price (11/19/2026): $0.5287 | Market Cap: $3.1 MilSector: Health Care | Industry: Life Sciences Tools & Services

iSpecimen (ISPC)


Market Price (11/19/2026): $0.5287
Market Cap: $3.1 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -565%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Personalized Diagnostics, Show more.

Weak multi-year price returns
2Y Excs Rtn is -124%, 3Y Excs Rtn is -168%

Penny stock
Mkt Price is 0.5

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -9.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2020%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -92%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -44%, Rev Chg QQuarterly Revenue Change % is -79%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1502%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1867%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1549%

High stock price volatility
Vol 12M is 113%

Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22%

Key risks
ISPC key risks include [1] its severe financial distress and ability to continue as a going concern, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -565%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Personalized Diagnostics, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -124%, 3Y Excs Rtn is -168%
3 Penny stock
Mkt Price is 0.5
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -9.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2020%
5 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -92%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -44%, Rev Chg QQuarterly Revenue Change % is -79%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1502%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1867%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1549%
8 High stock price volatility
Vol 12M is 113%
9 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22%
10 Key risks
ISPC key risks include [1] its severe financial distress and ability to continue as a going concern, Show more.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 18: down 10.6% in one day (S&P 500 down 0.3%)
The stock declined without company news. The S&P 500 also decreased, but by a smaller percentage.

Down 77.6% since its Aug 19 high (S&P 500 down 4.8%)
The stock experienced a significant decline without specific negative company news, while broader market sentiment indicated a tech selloff. The decline included sharp drops on August 21 without company news and October 16 amid a market-wide tech selloff.

Show more
Prices as of 11/18/2026

Nov 18: down 10.6% in one day (S&P 500 down 0.3%)
The stock declined without company news. The S&P 500 also decreased, but by a smaller percentage.

Down 77.6% since its Aug 19 high (S&P 500 down 4.8%)
The stock experienced a significant decline without specific negative company news, while broader market sentiment indicated a tech selloff. The decline included sharp drops on August 21 without company news and October 16 amid a market-wide tech selloff.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -71.8% change in ISPC stock from 7/31/2026 to 11/18/2026 was primarily driven by a -75.5% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611182026Change
Stock Price ($)1.890.53-71.8%
Change Contribution By: 
Total Revenues ($ Mil)10-54.6%
P/S Multiple0.61.6153.9%
Shares Outstanding (Mil)01-75.5%
Cumulative Contribution-71.8%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
ISPC-71.8% 
Market (SPY)-2.0%22.8%
Sector (XLV)11.9%9.3%

Fundamental Drivers

The -89.8% change in ISPC stock from 4/30/2026 to 11/18/2026 was primarily driven by a -84.8% change in the company's Shares Outstanding (Mil).
(LTM values as of)430202611182026Change
Stock Price ($)5.230.53-89.8%
Change Contribution By: 
Total Revenues ($ Mil)20-75.8%
P/S Multiple0.61.6177.4%
Shares Outstanding (Mil)01-84.8%
Cumulative Contribution-89.8%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
ISPC-89.8% 
Market (SPY)2.1%21.7%
Sector (XLV)25.1%4.0%

Fundamental Drivers

The -98.3% change in ISPC stock from 10/31/2025 to 11/18/2026 was primarily driven by a -95.5% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202511182026Change
Stock Price ($)31.200.53-98.3%
Change Contribution By: 
Total Revenues ($ Mil)60-92.1%
P/S Multiple0.31.6383.7%
Shares Outstanding (Mil)01-95.5%
Cumulative Contribution-98.3%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
ISPC-98.3% 
Market (SPY)8.2%20.6%
Sector (XLV)27.7%5.7%

Fundamental Drivers

The -99.9% change in ISPC stock from 10/31/2023 to 11/18/2026 was primarily driven by a -99.2% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202311182026Change
Stock Price ($)456.000.53-99.9%
Change Contribution By: 
Total Revenues ($ Mil)100-95.4%
P/S Multiple0.51.6213.3%
Shares Outstanding (Mil)01-99.2%
Cumulative Contribution-99.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
ISPC-99.9% 
Market (SPY)81.1%9.0%
Sector (XLV)52.9%4.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
ISPC Return9%-82%-64%-73%-90%-95%-100%
Peers Return53%-29%4%-9%3%46%54%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
ISPC Win Rate57%17%33%33%25%9% 
Peers Win Rate73%37%42%43%55%67% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
ISPC Max Drawdown--86%-76%-78%-91%-97% 
Peers Max Drawdown-17%-43%-30%-26%-33%-31% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRL, AZTA, LH, DGX, IQV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventISPCS&P 500
2025 US Tariff Shock
  % Loss-44.2%-18.8%
  % Gain to Breakeven79.2%23.1%
  Time to Breakeven162 days79 days
2024 Yen Carry Trade Unwind
  % Loss-16.5%-7.8%
  % Gain to Breakeven19.8%8.5%
  Time to Breakeven11 days18 days
2023 SVB Regional Banking Crisis
  % Loss-26.7%-6.7%
  % Gain to Breakeven36.4%7.1%
  Time to Breakeven59 days31 days

Compare to CRL, AZTA, LH, DGX, IQV

In The Past

iSpecimen's stock fell -44.2% during the 2025 US Tariff Shock. Such a loss loss requires a 79.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventISPCS&P 500
2025 US Tariff Shock
  % Loss-44.2%-18.8%
  % Gain to Breakeven79.2%23.1%
  Time to Breakeven162 days79 days
2023 SVB Regional Banking Crisis
  % Loss-26.7%-6.7%
  % Gain to Breakeven36.4%7.1%
  Time to Breakeven59 days31 days

Compare to CRL, AZTA, LH, DGX, IQV

In The Past

iSpecimen's stock fell -44.2% during the 2025 US Tariff Shock. Such a loss loss requires a 79.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About iSpecimen (ISPC)

iSpecimen Inc. (ISPC) operates a vital technology platform within the life sciences sector, serving as a connector between medical researchers and healthcare organizations worldwide. The company's primary function is to facilitate access to human biofluids, tissues, and living cells required for scientific research. It bridges the gap between those who need specific biological materials for their studies and the institutions that hold these valuable biospecimens, streamlining a critical component of medical advancement.

The core of iSpecimen's offering is its proprietary iSpecimen Marketplace, a cloud-based online platform. This innovative marketplace allows scientists to efficiently search for and secure access to a wide array of biospecimens and associated patient data from a global network comprising hospitals, laboratories, biobanks, and blood centers. Its primary customers include biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions, all of whom rely on timely and precise access to biospecimens to drive their research and development efforts.

AI Analysis | Feedback

Here are a couple of analogies for iSpecimen:

  • Think of it as an Amazon for medical research samples and data.

  • It's like an eBay for human biospecimens.

AI Analysis | Feedback

  • iSpecimen Marketplace Platform: A cloud-based online marketplace that connects life science researchers with healthcare organizations providing access to human biospecimens, subjects, and data.

AI Analysis | Feedback

iSpecimen (ISPC) sells primarily to other companies and institutions. Its major customers fall into the following categories:

  • Biopharmaceutical companies
  • In vitro diagnostic companies
  • Government/academic institutions

AI Analysis | Feedback

null

AI Analysis | Feedback

Katharyn Field, Chief Executive Officer, President, Secretary, and Treasurer

Ms. Field was appointed Chief Executive Officer, Secretary, and Treasurer of iSpecimen on November 7, 2025, and continues to serve as President, a role she assumed on February 28, 2025. Her background includes extensive experience in strategy consulting and executive leadership across both private and public sectors. Ms. Field is currently the CEO and Chairman of Halo Collective Inc., a cannabis company, a position she has held since May 2019. She also serves as an Executive Director at Akanda Corporation, a medical cannabis company, since June 2022, and as a director of Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, since July 2024. In 2014, Ms. Field played a pivotal role in the procurement, build-out, and sale of one of the original vertically integrated licensed medical marijuana treatment centers in Florida. She previously operated a strategy consulting practice focused on cannabis and served as Executive Vice President of Corporate Development at MariMed from 2018 to 2019. Her career also includes prominent positions at The White House, The Brookings Institution, and Bain & Company. Ms. Field holds an MBA in Economics from Columbia Business School and a BA in Public Policy with honors from Stanford University.

Yuying Liang, Chief Financial Officer

Mr. Liang was appointed Chief Financial Officer of iSpecimen on December 13, 2024. He is a certified public accountant (CPA) with significant experience in corporate accounting, financial reporting, and CFO services. Mr. Liang has provided financial leadership and strategic guidance to numerous public and private companies across various sectors.

Eric Langlois, Chief Revenue Officer

Mr. Langlois was appointed Chief Revenue Officer in January 2023. He joined iSpecimen in 2016 and previously served as the Senior Vice President of Sales and Business Development, during which time he led the company to 3,000 percent revenue growth. Prior to joining iSpecimen, Mr. Langlois served as Global Head of Sales for The Reprocell Group, where he was responsible for integrating sales teams across four portfolio companies focused on cellular reprogramming, stem cells, 3D cell culture, genomics, and biospecimens. He has over 25 years of experience in life science research, having held senior sales roles at companies such as Genomics Collaborative, SeraCare Life Sciences, SeqWright, and BioServe. Mr. Langlois holds a BS in Biotechnology/Biochemistry from Worcester Polytechnic Institute.

Annette Arnold, Senior Vice President, Sales & Business Development

Ms. Arnold is responsible for driving and managing all aspects of iSpecimen's sales and business development efforts. She brings over 20 years of experience excelling in sales within the biospecimen market, applying her strategic vision, negotiation skills, and management expertise. She plays a crucial role in developing the company's supply partner network to meet growing customer demand.

Carly Lejnieks, Senior Vice President, Marketing

Ms. Lejnieks and her team focus on presenting iSpecimen's unique offerings to life science customers who require streamlined and compliant solutions for procuring human biospecimens. She has over 20 years of experience leading marketing strategies, integrated programs, and high-growth initiatives for organizations in the life science industry. Before joining iSpecimen, Ms. Lejnieks worked as a marketing consultant for more than a decade, serving clients in the healthcare and life science sectors.

AI Analysis | Feedback

The key risks to iSpecimen's business are primarily centered around its financial viability and the sustainability of its core operations.

  1. Financial Solvency and Going Concern Doubt: iSpecimen faces a severe liquidity crisis and operational challenges, marked by a dramatic decline in revenue and significant net losses. The company's Q3 2025 report showed a 96% year-over-year revenue plummet and a widening net loss. Management has expressed substantial doubt about the company's ability to continue as a going concern, underscored by a low current ratio and insufficient cash runway.
  2. Significant Revenue Contraction and Lack of Sustainable Business Model: The core biospecimen marketplace model has experienced a near-total collapse in revenue, raising serious questions about its effectiveness and long-term viability. The company also relies on a relatively small number of customers for a substantial portion of its revenue and does not operate on a recurring revenue model, making its income streams unstable and highly susceptible to changes in demand or customer attrition.
  3. High Volatility and Shareholder Dilution Risk: iSpecimen's stock price has been highly volatile. Recent and planned issuances of shares, including a significant number registered for resale from Series C preferred conversions, pose a substantial risk of diluting existing shareholder value and exerting downward pressure on the stock price. This also impacts the company's ability to maintain its Nasdaq listing.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable market for iSpecimen's main products and services is the global human biospecimens market. This market was valued at USD 12.42 billion in 2024 and is projected to reach USD 26.45 billion by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 7.85% from 2025 to 2034.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for iSpecimen (ISPC)

  • Expansion of AI-Driven Capabilities: iSpecimen recently launched an AI agent designed to revolutionize biospecimen matching, indicating a strategic focus on leveraging artificial intelligence. The company plans to further expand its AI features to include automated monitoring and validation of regulatory submissions, enhance automation of high-compliance and data-intensive workflows, and improve intelligent lead qualification and outreach management. These advancements are expected to streamline operations and enhance the efficiency and appeal of its marketplace.
  • Increased Demand and Diversification of Biospecimen Offerings: iSpecimen is experiencing growing interest from clients seeking a broader range of specimen types, including FFPE (formalin-fixed paraffin-embedded) and fresh frozen (FF) tissue. The company has also demonstrated its capability for rapid procurement, such as successfully collecting 500 influenza swab samples in a short timeframe for a customer research project, which has led to ongoing engagement for future respiratory sampling needs. This expansion in offerings and demonstrated responsiveness are anticipated to attract and retain more customers.
  • Digital Transformation and Marketplace Optimization: Recent announcements include the completion of "Milestone 2: System Integration and Marketplace Activation" in February 2026, as part of iSpecimen's digital transformation initiatives. Enhancements to its proprietary online marketplace platform, which connects researchers with human biofluids, tissues, and living cells, are expected to improve user experience, increase operational efficiency, and facilitate greater transaction volume.
  • Penetration of the Growing Contract Research Services Market: iSpecimen's core business operates within the broader contract research services market for biospecimens, a sector projected to reach $13.5 billion by 2032 with a compound annual growth rate (CAGR) of 13.3%. Despite current financial challenges, the underlying large and expanding market for biospecimen procurement represents a significant long-term opportunity for the company to capture increased market share.

AI Analysis | Feedback

Share Issuance:
  • iSpecimen completed its initial public offering (IPO) in June 2021, issuing 2,250,000 shares of common stock at $8.00 per share, resulting in gross proceeds of $18,000,000.
  • The company experienced substantial share dilution, with the number of shares outstanding increasing by 76.4% in Q3 2025 and by 915% over the prior year.
  • In 2025, iSpecimen undertook equity raises totaling approximately $5.75 million, which included a $3,999,574 underwritten offering and a $1,749,998 private placement. A private placement announced on December 30, 2025, introduced more shares into the market for approximately $5.5 million through the issuance of Series C Convertible Preferred Stock.
Inbound Investments:
  • In June 2021, iSpecimen raised $18,000,000 in gross proceeds from its initial public offering.
  • The company announced a private placement of approximately $5.5 million on December 30, 2025.
  • During 2025, iSpecimen secured approximately $5.75 million through an underwritten offering and a private placement.
Capital Expenditures:
  • iSpecimen reported minimal capital expenditures, with $32,000 in CapEx consuming most of its -$8.3 million in operating cash flow.
  • In Q3 2025, the company recorded $0 in capital expenditures.
  • The net proceeds from the 2021 IPO were earmarked for various corporate expenses, including technology development, sales and marketing, supply development, and customer acquisition.

Better Bets vs. iSpecimen (ISPC)

Peer Outperformance in Life Sciences Tools & Services

ISPC has trailed 95% of its 109 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that ISPC has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
2%
of 125 industry peers · -97.6% return
3Y
3%
of 115 industry peers · -99.9% return
5Y
5%
of 109 industry peers · -100.0% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten ISPC by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is ISPC's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services ← 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

ISPCCRLAZTALHDGXIQVMedian
NameiSpecimenCharles .Azenta Labcorp Quest Di.IQVIA  
Mkt Price0.53333.3149.40370.78260.00258.06259.03
Mkt Cap0.015.92.230.128.642.522.3
Rev LTM03,97761414,59411,84117,3117,909
Op Inc LTM-9535-231,6451,7282,3931,090
FCF LTM-9400101,2871,3752,079843
FCF 3Y Avg-7501281,1701,2642,084836
CFO LTM-7622381,8151,9512,7361,219
CFO 3Y Avg-6723621,6691,7442,7061,196

Growth & Margins

ISPCCRLAZTALHDGXIQVMedian
NameiSpecimenCharles .Azenta Labcorp Quest Di.IQVIA  
Rev Chg LTM-92.1%-1.2%4.8%6.0%9.1%8.8%5.4%
Rev Chg 3Y Avg-44.0%-1.9%1.0%6.6%8.5%5.3%3.1%
Rev Chg Q-78.7%-2.2%12.0%6.9%10.0%8.0%7.5%
QoQ Delta Rev Chg LTM-54.6%-0.6%2.9%1.7%2.4%1.9%1.8%
Op Inc Chg LTM14.4%50.3%15.3%20.6%12.5%6.0%14.9%
Op Inc Chg 3Y Avg5.6%-0.3%23.1%12.0%15.3%7.4%9.7%
Op Mgn LTM-2,020.0%13.5%-3.7%11.3%14.6%13.8%12.4%
Op Mgn 3Y Avg-768.0%11.8%-4.3%10.0%14.0%14.1%10.9%
QoQ Delta Op Mgn LTM-1,058.7%1.8%-0.3%-0.1%0.4%-0.1%-0.1%
CFO/Rev LTM-1,502.0%15.7%6.2%12.4%16.5%15.8%14.0%
CFO/Rev 3Y Avg-549.7%18.0%11.2%12.2%16.2%16.8%14.2%
FCF/Rev LTM-1,866.6%10.0%1.6%8.8%11.6%12.0%9.4%
FCF/Rev 3Y Avg-680.5%12.5%5.0%8.5%11.7%12.9%10.1%

Valuation

ISPCCRLAZTALHDGXIQVMedian
NameiSpecimenCharles .Azenta Labcorp Quest Di.IQVIA  
Mkt Cap0.015.92.230.128.642.522.3
P/S1.64.03.62.12.42.52.4
P/Op Inc-0.129.8-98.418.316.617.817.2
P/EBIT-0.11,737.9-98.420.716.318.217.2
P/E-0.1396.5-18.230.025.330.527.6
P/CFO-0.125.658.916.614.715.516.1
Total Yield-1,545.2%0.3%-5.6%4.1%5.2%3.3%1.8%
Dividend Yield0.0%0.0%0.0%0.8%1.3%0.0%0.0%
FCF Yield 3Y Avg-232.9%5.1%1.8%5.1%5.9%5.4%5.1%
D/E0.30.20.00.20.20.40.2
Net D/E-5.70.2-0.10.20.20.30.2

Returns

ISPCCRLAZTALHDGXIQVMedian
NameiSpecimenCharles .Azenta Labcorp Quest Di.IQVIA  
1M Rtn-41.9%11.1%41.8%16.3%10.7%-2.9%10.9%
3M Rtn-77.8%14.9%38.7%12.4%7.9%3.5%10.2%
6M Rtn-84.5%113.6%166.0%44.7%35.2%50.5%47.6%
12M Rtn-97.6%105.1%67.9%44.2%42.7%18.8%43.4%
3Y Rtn-99.9%76.3%-10.4%80.1%104.0%26.0%51.2%
1M Excs Rtn-41.1%9.5%42.2%18.6%13.5%0.2%11.5%
3M Excs Rtn-73.8%17.3%38.3%14.6%11.1%3.7%12.8%
6M Excs Rtn-84.2%113.8%166.2%45.0%35.5%50.7%47.8%
12M Excs Rtn-108.8%93.7%56.9%32.1%30.8%8.2%31.5%
3Y Excs Rtn-167.4%27.9%-65.8%18.5%39.7%-34.9%-8.2%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Biospecimens29   
Shipping and other  100
Specimens – contracts with customers  91011
Total29101011


Net Income by Segment
$ Mil20252024
Biospecimens-10-12
Total-10-12


Assets by Segment
$ Mil20252024
Biospecimens109
Total109


Price Behavior

Price Behavior
Market Price$0.53 
Market Cap ($ Bil)0.0 
First Trading Date06/17/2021 
Distance from 52W High-97.6% 
   50 Days200 Days
DMA Price$1.01$3.98
DMA Trenddowndown
Distance from DMA-47.3%-86.6%
 3M1YR
Volatility79.5%112.6%
Downside Capture424.14403.63
Upside Capture-200.98-64.90
Correlation (S&P 500)18.2%18.8%
ISPC Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.941.571.711.361.790.94
Up Beta-1.81-0.523.192.631.140.62
Down Beta0.311.301.611.122.351.45
Up Capture-19%-16%-64%-83%-30%-5%
Bmk +ve Days12182862130427
Stock +ve Days915264595296
Down Capture443%373%327%251%186%113%
Bmk -ve Days10253664121325
Stock -ve Days12253476151437

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ISPC
ISPC-97.7%112.6%-2.80-
Sector ETF (XLV)21.5%17.0%0.965.8%
Equity (SPY)10.9%13.8%0.4919.2%
Gold (GLD)-8.2%29.0%-0.302.4%
Commodities (DBC)28.8%21.5%1.07-10.1%
Real Estate (VNQ)11.2%14.2%0.505.9%
Bitcoin (BTCUSD)-29.6%43.7%-0.6914.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ISPC
ISPC-83.8%151.6%-0.60-
Sector ETF (XLV)8.0%15.4%0.336.9%
Equity (SPY)11.0%17.3%0.4610.4%
Gold (GLD)14.5%19.2%0.60-0.2%
Commodities (DBC)6.8%19.6%0.24-2.7%
Real Estate (VNQ)1.1%19.0%-0.056.9%
Bitcoin (BTCUSD)-0.0%51.4%0.189.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ISPC
ISPC-60.5%147.6%-0.58-
Sector ETF (XLV)12.1%16.8%0.597.1%
Equity (SPY)14.9%18.0%0.7010.6%
Gold (GLD)10.9%16.6%0.53-0.6%
Commodities (DBC)7.2%18.2%0.31-2.0%
Real Estate (VNQ)5.8%20.7%0.247.0%
Bitcoin (BTCUSD)57.1%66.3%0.979.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.3 Mil
Short Interest: % Change Since 1015202692.2%
Average Daily Volume0.4 Mil
Days-to-Cover Short Interest1
Basic Shares Quantity1.4 Mil
Short % of Basic Shares21.9%

Earnings Returns History

Updated 11/9/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/20244.8%11.4%8.8%
5/7/20247.7%-18.5%16.1%
3/14/2024-21.8%-34.8%-50.7%
11/2/2023-5.6%-12.6%-17.5%
8/2/2023-9.9%-13.2%-41.7%
5/4/2023-3.4%-4.6%-23.0%
3/14/2023-3.0%-3.7%-8.1%
11/8/2022-3.7%4.9%-12.3%
...
SUMMARY STATS   
# Positive224
# Negative10108
Median Positive6.3%8.2%9.8%
Median Negative-5.8%-11.0%-16.3%
Max Positive7.7%11.4%16.1%
Max Negative-21.8%-34.8%-50.7%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/20244.8%11.4%8.8%
5/7/20247.7%-18.5%16.1%
3/14/2024-21.8%-34.8%-50.7%
11/2/2023-5.6%-12.6%-17.5%
8/2/2023-9.9%-13.2%-41.7%
5/4/2023-3.4%-4.6%-23.0%
3/14/2023-3.0%-3.7%-8.1%
11/8/2022-3.7%4.9%-12.3%
8/4/2022-14.0%-10.1%-15.1%
5/10/2022-6.0%-7.5%10.9%
2/17/2022-6.9%-11.9%-12.3%
8/10/2021-1.6%-6.7%3.9%
SUMMARY STATS   
# Positive224
# Negative10108
Median Positive6.3%8.2%9.8%
Median Negative-5.8%-11.0%-16.3%
Max Positive7.7%11.4%16.1%
Max Negative-21.8%-34.8%-50.7%

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/202608/14/202610-Q
03/31/202605/18/202610-Q
12/31/202504/01/202610-K
09/30/202511/17/202510-Q
06/30/202508/14/202510-Q
03/31/202505/19/202510-Q
12/31/202404/14/202510-K
09/30/202411/07/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202303/13/202410-K
09/30/202311/02/202310-Q
06/30/202308/02/202310-Q
03/31/202305/04/202310-Q
12/31/202203/21/202310-K
09/30/202211/08/202210-Q
Collapse to Preview
Report DateFiling DateFiling
06/30/202608/14/202610-Q
03/31/202605/18/202610-Q
12/31/202504/01/202610-K
09/30/202511/17/202510-Q
06/30/202508/14/202510-Q
03/31/202505/19/202510-Q
12/31/202404/14/202510-K
09/30/202411/07/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202303/13/202410-K
09/30/202311/02/202310-Q
06/30/202308/02/202310-Q
03/31/202305/04/202310-Q
12/31/202203/21/202310-K
09/30/202211/08/202210-Q
06/30/202208/04/202210-Q
03/31/202205/10/202210-Q
12/31/202103/22/202210-K
09/30/202111/04/202110-Q
06/30/202108/10/202110-Q
03/31/202106/18/2021424B4
09/30/202011/19/2020S-1
Core Cache Last Updated: 11/18/2026